ON eNews
November 2020
Demands Are Never Final, They Just Evolve Welcome to the November 2020 edition of the One Nucleus eNews. I hope you are remaining well and productive through this prolonged and constantly changing dynamic that creates new demands on everyone’s strategies, resources and time. Even as I write this introduction, I am conscious you taking the time to read it is creating in itself a demand on your time, so I shall endeavour to ensure it provides you with useful information and updates to make it rewarding as you navigate through. Seeking New Deals & Innovations: Asking many of our network about what demanded their time and resource before Covid-19 would often receive a reply that it was the time, cost and energy levels of seeking their next investment or partnering deal. It has been remarkable to see the strength and resilience of our sector with record levels of investment secured and hugely exciting deals such as those announced by Inivata and Horizon. We continue to profile and connect our members to facilitate deal flow. New Tools and Supply Chain Resilience: R&D is a demanding beast and requires lab reagent and equipment suppliers to continue being innovative in the research tools they develop. Releases of new lab products recently have included those reported by AMSBIO and BoIVT. Ensuring you plan for potential supply change disruptions has intense relevance and demands consideration at present as the January 1st Brexit deadline approaches. To this end, it was extremely helpful to have the Office for Life Sciences and Thermo Fisher present to our members on how to prepare in order to remain resilient. If you missed the online session you can access the recording of the webinar via our on-demand content page. Making Your Next Contact: The move to online events has revealed several benefits and disadvantages as discussed in previous issues. One challenge that has demanded attention has been the loss of face-toface networking. The digital 1-2-1 partnering meetings have functioned well. That said, we repeatedly hear from all parts of the sector, especially those providing services and consultancy that networking events were key. We continue to evolve our approach to address this as you may have seen. It was a pleasure to host the ‘My question is …’ Networking Lunch last week and the collaborative event this week with our friends in New Jersey. Utilising the Zoom breakout rooms in a manner to enable groups to move beyond the self-help dynamic of ‘I’m xxx and I have this problem’ to a focussed discussion topic where they can get to build rapport and potential follow up. Do check out the blog from the networking lunch. If you have a burning question you’d like to submit for our next one on 30th November do email it to alicia@ onenucleus.com for consideration. We know many of our members leverage the networking heavily in normal times to generate relationships and business pipelines, so we welcome your engagement in these online formats.
2
Demanding New: One Nucleus is fortunate enough to work within a sector that continually innovates to herald in new approaches to improve patient outcomes. For our small part in this, we demand being innovative of ourselves and I look forward to updating you on some new initiatives in the coming weeks. The pandemic has forced us to do some things new of course and that includes Genesis going digital on December 10th. Two decades after starting, this feels a little like launching Genesis 2.0, but I mention here since I would urge you to take a look at the details and explainer video described below. Many times, along with the excellent content and exhibition, I feel Genesis has always been that hub of human collisions where we catch up as a community pre-Xmas. That works easily when you can mingle through the day, randomly bumping into contacts when sometimes only moving a few paces. This is how we check in on what our peers are up to and how they doing. Evolving the functionality as we learn, I am really pleased to see this year the Genesis conference app will enable those chance collisions in as near the same manner as possible for all our delegates. Come join the fun! As well as more about the above, this issue will update you on how we can support you in maintaining your profile, increase your savings as we widen access to elements of our Purchasing Scheme and inform you of upcoming opportunities. Tony Jones, CEO, One Nucleus
On-Demand Content Since the beginning of the first lockdown, we have held all of our events digitally with recordings of each made available to members. See below for a short list of what is available and click here for the full list and how to access. • All sessions from ON Helix 2020. Programme can be found here • BioWednesday Webinar: What Role Can Laboratory Automation Play Post Lockdown? • The Way Back to Business Travel Post COVID-19 Webinar • Career Pathways Webinar: Progressing to Senior Lab and Non-Lab Based Roles • BioWednesday Webinar: Leading Teams Through Uncertainty • BioWednesday Webinar: How Will Covid-19 Influence Site Selection for Future Trials? • Bringing Purpose to Being the Employer of Choice Webinar
• Life Science Marketing Group: Communicating Your Way Out of COVID
Annual Review & Directory Update Our updated Annual Review & Directory is now live! Filled with industry articles on Covid-19, an overview of the East of England Collective Assets, and an updated member directory. View the new edition here.
Purchasing Scheme Announcement One Nucleus is pleased to announce that two of the current Preferred Suppliers are now available for all members to use:
Deliver Plus is not just another delivery company, Deliver Plus is a parcel management company: they utilize the services from the world’s best carriers; UPS, DHL and FedEx, managing the process on your behalf from collection through to delivery. How do they do that? Well as you may know delays can and do occur to parcels in transit, they pro-actively track, monitor and resolve issues on your behalf, so you don’t have to. Offering a seamless service that saves you time, money and, most importantly, offers you added peace of mind Parcel management is a new concept in logistics but one that is already adding value to the supply chains of One Nucleus members for example: Essen BioScience and Cytocell. They ship over 500,000 parcels a year to the UK, EU and 220 countries worldwide on behalf of companies just like yours. If you would like to find out more or would like to setup an account please contact Dan McGeoghan via e-mail dan@deliverplus.co.uk or 0845 5001050.
Harts has been established since 1836 and is a leading UK independent dealer providing a ‘Single Source’ for all One Nucleus Members’ office requirements. In February 2018 Harts became part of the Bluefish Group, who are centrally located in Northampton. Like Harts, Bluefish has an established history and share the same company values, this has allowed Harts to continue to grow whilst giving them the procurement benefits of being part of a larger company. This has enabled them to stay focussed on the local market and helping them deliver additional benefits to our customers. Harts have built a reputation within One Nucleus over many years, based upon competitive pricing, excellent, fast and professional customer service dedicated to One Nucleus members, with a Local and National Distribution network in place, and a stock holding in excess of £5M of products, all available for next-day delivery. If you would like to find out more or would like to setup an account please contact Neil Wilder via e-mail neilw@bluefish.group or 07885 663249. Richard can perform a cost-benefit analysis for members and give more information on the scheme by contacting him on 01223 896453 or Richard@onenucleus.com
genesis digital 10 December 2020
BioNewsRound Award - FINAL CALL Calling for exciting sector press releases! The BioNewsRound Award is coming back and this year will allow the six finalists to pitch in the lead up to Genesis. The vote will then run before and during the conference via the app and the winner will be announced before the closing networking session. How does it work? Companies are now invited to submit an announcement or press release from within the past 12 months that has had a significant impact on the life science sector as a whole or patients. Deadline for submission is 13 November 2020. You can submit an entry by contacting genesis@onenucleus.com.
App Launch We’ll soon be launching the Genesis Conference App! The conference app is the cornerstone of the conference with exclusive content only available via the app to all registered delegates. You can connect with other delegates, arrange 1-2-1 virtual meetings, profile yourself and company and join Innovation Workshops, all prior to the event.
Find out more
Upcoming Webinars & Digital Events One Nucleus Events 11 Nov | BioWednesday Webinar: Technologies to Deliver the Promise of Cell and Gene Therapies - register 17 Nov | Life Science Marketing Group: Digital Marketing - Top Tips for Life Science Businesses - register 18 Nov | SLAS & ON Webinar Series: Turn Your Lab Automation Plans Into Action – Part 2 - register 20 Nov | The Impact of the US Election on Financial Markets - register 30 Nov | My Question is… Networking Lunch Meeting - register 02 Dec | SLAS & ON Webinar Series: Turn Your Lab Automation Plans Into Action – Part 3 - register 10 Dec | Genesis Digital 2020 - register
Industry Events 09 Nov | AI & Robotics in Neurocritical Care & Neurosurgery - find out more 09-12 Nov | Member Discount Available: Virtual Partnering: Neurosciences - find out more 10 Nov | Modern Cell Based Assays - Virtual Symposium - find out more 11 Nov | Responsible Person - Refresher - find out more 11 Nov | Discover the Latest Funding, Drug Development and Clinical Solutions Strategies find out more 12 Nov | The UK’s New Immigration System After Brexit: is Your Business Ready? - find out more 12 Nov | Commercialising Life Sciences w. Silicon Valley Bank - find out more 16 Nov | Free for members: Bio Integrates 2020 - find out more
Corporate Patron
17 Nov | Free for members: Pharma Integrates Digital 2020 - find out more 17 Nov | BioBeat20 - find out more 18 Nov | Cambridge New Therapeutics Forum (CamNTF) - find out more 19 Nov | How to Retain, Recruit & Motivate Your Overseas Hires w. KPMG UK find out more 20 Nov | UK Bio Lab Network - November Meeting - find out more 26 Nov | Early Drug Development: Strategy and Solution - find out more 28 Nov | RAREfest20 - find out more 02-04 Dec | Member Discount Available: Virtual Partnering: Infectious Diseases find out more 14 Dec | Leadership and Influencing Skills - find out more
Corporate Sponsors
6
Member Highlight IP Due Diligence - a workshop from ON Helix 2020 An overview of the main term sheets requirements in terms of Intellectual Property including freedom to operate, warranties and discussion on how to get them right. Teresa Lavoie, Fish&Richardson Colin McCall, Taylor Wessing
Click here to view this workshop.
Deal of the Month Abcam Raises $180m on NASDAQ Abcam, the antibody, reagents and kits world leader has joined the ranks of the Nasdaq listed companies this month. Already on the London Stock Exchange, Abcam sought an initial public offering on the American stock market to increase its visibility in the marketplace as well as obtaining additional capital. And it proved successful as the offering filled at $100M, finalised at $180M that will be used for ‘general corporate purposes and to fund incremental growth, including for possible acquisitions’. Abcam has developed its offer on discovery partnerships including data-driven expertise and full cycle support to go beyond the strict antibody supply. Surely this appetite of American market will reinforce Abcam developments in the support space making them important partners of future therapeutics development.
Funding & Support INNO4COV-19 Boosting Innovation for COVID-19 Diagnostic, Prevention and Surveillance This is an Open Call for funding from a European programme to catalyse the development and commercialisation of technologies and products to combat Covid-19. The initial deadline is 30 November 2020 and the aim is to accelerate the deployment of ideas in via the ‘Lab to Fab’ Platform including innovative diagnostics and screening, environmental surveillance, telemedicine and PPE. The benefits available include access to the following: • • • •
Financial support - up to €100K (100% funded) Access to specific facilities and infrastructure Tailored support and guidance - technical, regulatory, business development and market introduction strategy Media exposure
Find out more here.
